Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma

被引：0
|
作者：
Weller, Michael
Papachristodoulou, Alexandros
Hentschel, Bettina
Gramatzki, Dorothee
Felsberg, Joerg
Loeffler, Markus
Schackert, Gabriele
Westphal, Manfred
Tonn, Joerg
Silginer, Manuela
von Deimling, Andreas
Pietsch, Torsten
Reifenberger, Guido
Roth, Patrick
机构：
[1] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland
[2] Univ Leipzig, Inst Med Informat Stat & Epidemol, Leipzig, Germany
[3] Heinrich Heine Univ Hosp, Dept Neuropathol, Dusseldorf, Germany
[4] Univ Hosp Dresden, Dept Neurosurg, Dresden, Germany
[5] Univ Hamburg, Dept Neurosurg, Hamburg, Germany
[6] Univ Munich LMU, Dept Neurosurg, Munich, Germany
[7] Heidelberg Univ, Dept Neuropathol, Heidelberg, Germany
[8] Univ Bonn, Dept Neuropathol, Bonn, Germany
[9] Univ Hosp Zurich, Zurich, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2013
引用
收藏
页数：1
相关论文
共 50 条
  • [41] INCIDENCE OF TREATMENT-ASSOCIATED IMAGING CHANGES IN NEWLY DIAGNOSED MGMT PROMOTER-METHYLATED GLIOBLASTOMA TREATED WITH CILENGITIDE (EORTC 26071-CENTRIC STUDY): INTERIM ANALYSIS
    Flies, C. M.
    Friedrich, M.
    Lohmann, P.
    van Garderen, K.
    Smits, M.
    Tonn, J. C.
    Weller, M.
    Galldiks, N.
    Snijders, T. J.
    NEURO-ONCOLOGY, 2022, 24
  • [42] A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status
    Vazquez-Blomquist, Dania
    Leenstra, Sieger
    van der Kaaij, Marielle
    Villarreal, Adelaida
    Bello-Rivero, Iraldo
    MOLECULAR BIOLOGY REPORTS, 2020, 47 (07) : 5263 - 5271
  • [43] A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status
    Dania Vázquez-Blomquist
    Sieger Leenstra
    Mariëlle van der Kaaij
    Adelaida Villarreal
    Iraldo Bello-Rivero
    Molecular Biology Reports, 2020, 47 : 5263 - 5271
  • [44] TERT promoter mutation as poor prognosis marker in glioblastoma via sphere formation and self- renewal capacity
    Lee, Jae-Ho
    Lee, Hyunsu
    Woo, Seon Rang
    Joo, Kyeung-Min
    Park, KeonUk
    CANCER RESEARCH, 2015, 75
  • [45] Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma
    Maxime Fontanilles
    Florent Marguet
    Ludivine Beaussire
    Nicolas Magne
    Louis-Ferdinand Pépin
    Cristina Alexandru
    Isabelle Tennevet
    Chantal Hanzen
    Olivier Langlois
    Fabrice Jardin
    Annie Laquerrière
    Nasrin Sarafan-Vasseur
    Fréderic Di Fiore
    Florian Clatot
    Acta Neuropathologica Communications, 8
  • [46] Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma
    Fontanilles, Maxime
    Marguet, Florent
    Beaussire, Ludivine
    Magne, Nicolas
    Pepin, Louis-Ferdinand
    Alexandru, Cristina
    Tennevet, Isabelle
    Hanzen, Chantal
    Langlois, Olivier
    Jardin, Fabrice
    Laquerriere, Annie
    Sarafan-Vasseur, Nasrin
    Di Fiore, Frederic
    Clatot, Florian
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2020, 8 (01)
  • [47] Glioblastoma with FGFR3-TACC3 fusion and TERT promoter mutation: A case report and review of the literature
    Zenezan, D.
    Rong, Y.
    Akhtar, I.
    Jhala, N.
    Seth, A.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2023, 82 (06): : 527 - 528
  • [48] A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548
    Weller, Michael
    Lim, Michael
    Idbaih, Ahmed
    Steinbach, Joachim
    Finocchiaro, Gaetano
    Raval, Raju
    Ashby, Lynn
    Ansstas, George
    Baehring, Joachim
    Taylor, Jennie
    Honnorat, Jerome
    Petrecca, Kevin
    De Vos, Filip
    Wick, Antje
    Sumrall, Ashley
    Roberts, Mustimbo
    Slepetis, Ruta
    Warad, Deepti
    Lee, Michelle
    Reardon, David
    Omuro, Antonio
    NEURO-ONCOLOGY, 2021, 23 : 55 - 56
  • [49] CLINICAL PRESENTATION OF "MOLECULAR GLIOBLASTOMA" IS DIFFERENT COMPARED TO "HISTOLOGICAL GLIOBLASTOMA", BUT OUTCOME IS THE SAME, REGARDLESS OF GRADE OR PRESENCE OF ONLY A TERT PROMOTER MUTATION
    Wijnenga, M. M. J.
    Maas, S. L. N.
    van Dis, V.
    Tesileanu, C. M. S.
    Kros, J. M.
    Dirven, L.
    Hazelbag, H. M.
    Dubbink, H. J.
    Vincent, A. J. P. E.
    French, P. J.
    van den Bent, M. J.
    NEURO-ONCOLOGY, 2023, 25
  • [50] Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis (vol 3 VDAA082 2021)
    Alnahhas, Iyad
    Alsawas, Mouaz
    Rayi, Appaji
    Palmer, Joshua D.
    Raval, Raju
    Ong, Shirley
    Giglio, Pierre
    Murad, Mohammad Hassan
    Puduvalli, Vinay
    NEURO-ONCOLOGY ADVANCES, 2021, 3 (01)
12345